Hannah Chang
Direktor/Vorstandsmitglied bei Gemini Therapeutics Sub, Inc.
Profil
Hannah H.
Chang is currently a managing director at Beijing Shuanghu Investment Management Co. Ltd., a director at Gemini Therapeutics Sub, Inc., a director at Inipharm, Inc., a director at Ray Therapeutics, Inc., and a director at Nuvig Therapeutics, Inc. She previously worked as an associate at 5AM Venture Management LLC from 2014 to 2017.
Dr. Chang received a doctorate from Harvard University, an undergraduate degree from Princeton University, and a graduate degree from Harvard Medical School.
Aktive Positionen von Hannah Chang
| Unternehmen | Position | Beginn |
|---|---|---|
Gemini Therapeutics Sub, Inc.
 Gemini Therapeutics Sub, Inc. BiotechnologyHealth Technology Gemini Therapeutics Sub, Inc. engages in the development of treatments for age-related macular degeneration (AMD) and linked ocular disorders. Its multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. The company was founded by James McLaughlin, Johanna Seddon, Paul Barlow and Andrew Herbert in 2015 and is headquartered in Cambridge, MA. | Direktor/Vorstandsmitglied | - |
Inipharm, Inc.
 Inipharm, Inc. Pharmaceuticals: MajorHealth Technology Inipharm, Inc. provides health care services. The company was founded by Brian Farmer and Mike Gallatin in 2018 and is headquartered in Bellevue, WA. | Direktor/Vorstandsmitglied | 11.11.2020 |
Nuvig Therapeutics, Inc.
 Nuvig Therapeutics, Inc. BiotechnologyHealth Technology Nuvig Therapeutics, Inc. is a company that is focused on developing innovative therapies for patients with chronic autoimmune diseases. The company is based in Redwood City, CA. The company's goal is to induce natural mechanisms that restore immune homeostasis and rebalance immune function following inflammation. Nuvig Therapeutics was founded by Greg Coffey, Jeffrey V. Ravetch, Sheldon L. Koenig, Pamela B. Conley, Joanne M. Quan. Julie Anne Smith has been the CEO of the company since 2023. | Direktor/Vorstandsmitglied | - |
Ray Therapeutics, Inc.
 Ray Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Ray Therapeutics, Inc. is an American company that is developing a lead candidate, RTX-015, to treat retinitis pigmentosa, a degenerative retinal disease. Ray Therapeutics is based in an undisclosed location. The company's mission is to restore vision for people with retinal degeneration using optogenetics gene therapies. Ray Therapeutics is pursuing multiple drug development programs for a range of degenerative retinal diseases, focusing on preserving and restoring vision in patients using the ground-breaking science of optogenetics. The company was founded by Paul Bresge and Sean Ainsworth, with Paul Bresge serving as CEO since incorporation. | Direktor/Vorstandsmitglied | - |
Beijing Shuanghu Investment Management Co. Ltd.
 Beijing Shuanghu Investment Management Co. Ltd. Investment ManagersFinance Beijing Shuanghu Investment Management Co. Ltd. (Wu Capital), is an Independent Private Equity/Venture Capital firm founded in 2013. It is headquartered in Beijing, China and has offices in Hong Kong and San Francisco, USA. | Private Equity Investor | - |
Ehemalige bekannte Positionen von Hannah Chang
| Unternehmen | Position | Ende |
|---|---|---|
5AM Venture Management LLC
 5AM Venture Management LLC Investment ManagersFinance 5AM Venture Management LLC (5AM Ventures) is an Independent Venture Capital firm founded in 2002 by Andrew J. Schwab, Carin M. Rollins and John D. Diekman. The firm is headquartered in San Francisco, US. | Private-Equity-Analyst | 01.07.2017 |
Ausbildung von Hannah Chang
| Princeton University | Undergraduate Degree |
| Harvard Medical School | Graduate Degree |
| Harvard University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
5AM Venture Management LLC
5AM Venture Management LLC Investment ManagersFinance 5AM Venture Management LLC (5AM Ventures) is an Independent Venture Capital firm founded in 2002 by Andrew J. Schwab, Carin M. Rollins and John D. Diekman. The firm is headquartered in San Francisco, US. | Finance |
Gemini Therapeutics Sub, Inc.
Gemini Therapeutics Sub, Inc. BiotechnologyHealth Technology Gemini Therapeutics Sub, Inc. engages in the development of treatments for age-related macular degeneration (AMD) and linked ocular disorders. Its multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. The company was founded by James McLaughlin, Johanna Seddon, Paul Barlow and Andrew Herbert in 2015 and is headquartered in Cambridge, MA. | Health Technology |
Inipharm, Inc.
Inipharm, Inc. Pharmaceuticals: MajorHealth Technology Inipharm, Inc. provides health care services. The company was founded by Brian Farmer and Mike Gallatin in 2018 and is headquartered in Bellevue, WA. | Health Technology |
Nuvig Therapeutics, Inc.
Nuvig Therapeutics, Inc. BiotechnologyHealth Technology Nuvig Therapeutics, Inc. is a company that is focused on developing innovative therapies for patients with chronic autoimmune diseases. The company is based in Redwood City, CA. The company's goal is to induce natural mechanisms that restore immune homeostasis and rebalance immune function following inflammation. Nuvig Therapeutics was founded by Greg Coffey, Jeffrey V. Ravetch, Sheldon L. Koenig, Pamela B. Conley, Joanne M. Quan. Julie Anne Smith has been the CEO of the company since 2023. | Health Technology |
Ray Therapeutics, Inc.
Ray Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Ray Therapeutics, Inc. is an American company that is developing a lead candidate, RTX-015, to treat retinitis pigmentosa, a degenerative retinal disease. Ray Therapeutics is based in an undisclosed location. The company's mission is to restore vision for people with retinal degeneration using optogenetics gene therapies. Ray Therapeutics is pursuing multiple drug development programs for a range of degenerative retinal diseases, focusing on preserving and restoring vision in patients using the ground-breaking science of optogenetics. The company was founded by Paul Bresge and Sean Ainsworth, with Paul Bresge serving as CEO since incorporation. | Commercial Services |
Beijing Shuanghu Investment Management Co. Ltd.
Beijing Shuanghu Investment Management Co. Ltd. Investment ManagersFinance Beijing Shuanghu Investment Management Co. Ltd. (Wu Capital), is an Independent Private Equity/Venture Capital firm founded in 2013. It is headquartered in Beijing, China and has offices in Hong Kong and San Francisco, USA. | Finance |
